PRINCETON, NJ / ACCESSWIRE / October 4, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet BioTherapeutics"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on October 3, 2022 infor
Full Story >>
Vote
+2